Introduction
============

Leukemia is the cancer of the body\'s blood-forming tissues, including the bone marrow and the lymphatic system ([@b1-ol-0-0-6688]). Despite advances in the understanding of the etiology of leukemia and the sub-classifications of the disease ([@b2-ol-0-0-6688]), the number of treatment alternatives for patients remain limited. Bone marrow transplantation has curative potential; however, this is only an option for a limited number of patients. Typical chemotherapy may be associated with poor efficacy, high toxicity and a limited survival time benefit ([@b3-ol-0-0-6688]). Traditional Chinese medicine (TCM), which originates from botanical, animal and mineral sources, has provided a rich resource for anticancer drug discovery that is attracting an increasing amount of interest ([@b4-ol-0-0-6688]).

Compound banmao capsule (CBC) is a traditional Chinese medicinal formula composed of extracts from 11 organisms, including *Mylabris phalerata* (banmao), *Panax ginseng* (radix ginseng), *Astragalus membranaceus* (radix astragali), *Eleutherococcus senticosus* (radix acanthopanax senticosus), *Rhizome sparganii, Scutellaria barbata*, *Curcuma zedoaria*, *Cornus officinalis*, *Ligustrum lucidum* ait, *Herba galii aparinis* and *Glycyrrhiza glabra* L. (radix glycyrrhizae). As the main component of CBC, banmao extract shows potential for anti-tumor capability as it has previously been demonstrated to directly kill tumor cells ([@b5-ol-0-0-6688]). Banmo has therefore been applied for the treatment of primary liver and lung cancer, rectal carcinoma, malignant lymphoma and gynecological tumors ([@b5-ol-0-0-6688]). However, the underlying mechanism for anti-tumor activity by CBC remains unknown.

Seropharmacology is a novel method for pharmacological study on Chinese *materia medicain vitro* using drug-containing serum ([@b6-ol-0-0-6688]). The essence of seropharmacology is the administration of drug to an experimental animal (for example, a rabbit, rat or mouse), followed by harvesting the animal blood and conducting *in vitro* pharmacological experiments with the drug-containing animal serum. The method has the same convenience as a typical *in vitro* experiment. Seropharmacology also provides a bioactive metabolite with the true pharmacological potency, having undergone biotransformation in the body of the laboratory animal. Therefore, it can be employed to study the biological effects of CBC.

In the present study, drug-containing animal serum was prepared, and insight into the mechanism underlying the anti-tumor effect of CBC was gained using the seropharmacological method.

Materials and methods
=====================

### Drugs and reagents

CBC (Shaanxi Huaxi Pharmaceutical Co., Ltd., Baoji, China) consists of 11 traditional Chinese drugs including Mylabris phalerata extract (banmao), radix ginseng, radix astragali, radix acanthopanax senticosus, Rhizomasparganii, Scutellaria barbata, Curcuma zedoaria, Cornus officinalis, Ligustrum lucidum ait. and Herba galii aparinis extracts, andradix glycyrrhizae. A total of one capsule of CBC was dissolved in 1 ml of PBS.

RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, propidium iodide (PI), RNase, trypsin and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) were from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The Annexin V-Fluorescein Isothiocyanate Apoptosis Detection kit I was obtained from BD Pharmingen (San Diego, CA, USA).

### Cell culture

K562 and HL60 human leukemia cells were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin in 5% CO~2~ at 37°C. At confluency, the cells were harvested with 0.25% trypsin in EDTA, counted and seeded. Confluent cells were used for the present study.

### Preparation of rat sera

The animal experiments were performed according to the Guidelines for the Care and Use of Laboratory Animals (Zhejiang University, Zhejiang, China). The present study was approved by the Ethics Committee of The First Affiliated Hospital, College of Medicine, Zhejiang University. Female Wistar rats weighing 200--250 g, aged 5--6 months were provided by the Shanghai Research Center for Model Organisms (China), and housed in a room with 22--25°C temperature, 50--60% relative humidity and a 12 h light/12 h dark cycle. All animals had free access to food and water. A total of 16 rats were used for drug containing serum preparation. Rats were randomly divided into vehicle control (n=8) and CBC (n=8) groups, and intragastrical administration of PBS and CBC (3x rat weight/65 kg) was then performed for 7 days. Blood was obtained from the heart of the rats (before sacrificing) following the last administration and serum was acquired by blood centrifugation at 2,000 × g for 20 min at 4°C. Following two filtration procedures with 0.22-µm cellulose acetate membranes, the sera were bottled, heated to inactivate at 56°C for 30 min and stored at −20°C until use.

### Assessment of relative viability with an MTS assay

K562 and HL60 cells were seeded into a 96-well plate at a density of 10^4^ cells/well and cultured in RPMI-1640 containing 10% drug-containing serum, control serum or control serum with 10 µg/ml norcantharidin (Shanghai Tauto Biotech Co., Ltd., Shanghai, China) for up to 72 h in the previously described conditions. The relative viability of the cells was quantified by measuring the amount of MTS converted by the cells. After 24, 48 or 72 h incubation with the treatment, 20 µl MTS was added to each well, incubated for another 2 h at 37°C and 5% CO~2~, and 25 µl/well of 10% SDS was subsequently added. The absorbance of each plate at 490 nm was measured with a spectrophotometer. All experiments were performed ≥3 times.

### Detection of apoptosis with Annexin V-fluorescein isothiocyanate (FITC)/PI staining

The rate of apoptosis in the K562 and HL60 cells was detected using flow cytometry. The cells were maintained in RPMI-1640 medium with 10% drug-containing or control serum for 72 h in the previously described conditions. Subsequently, cells were harvested, washed twice with PBS and resuspended in the binding buffer to a final concentration of 10^6^ cells/ml. Following the addition of Annexin V-FITC/PI solution, the cells were kept in the dark for 20 min at room temperature to stain the damaged DNA of the apoptotic cells. Subsequent to filtration using a 300-µm mesh strainer, the cells underwent apoptosis analysis by flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA; Canto II). All experiments were performed ≥3 times.

### Cell cycle distribution assessment

Subsequent to incubating the K562 and HL60 cells with drug-containing or control serum for 72 h, the harvested cells were seeded to a concentration of 10^6^ cells/ml, fixed with 70% ice-cold ethanol, incubated with 0.25% RNase at 37°C for 30 min and stained with 50 µg/ml PI according to the manufacturer\'s protocol. Subsequent to filtration with a 300-µm mesh strainer, the cells underwent cell cycle analysis by flow cytometry. All experiments were performed independently ≥3 times.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Subsequent to incubating human leukemia cell lines with drug-containing or control serum for 72 h, the total RNA from the harvested cells was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. RT-qPCR was performed with a One Step SYBR^®^ PrimeScript™ RT-qPCR kit (Takara Biotechnology Co., Ltd., Dalian, China) and an iQ5 Real-time PCR Detection system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The procedure was as follows: 95°C for 1 min for 40 cycles (95°C for 10 sec and 60°C 1 min). The mRNA of VEGF-A and chemotactic and inflammatory genes was detected with specific primers (Sangon Biotech Co., Ltd, Shanghai, China), as listed in [Table I](#tI-ol-0-0-6688){ref-type="table"}. Expression of the GAPDH gene was assessed simultaneously in all samples as an internal control. Relative gene expression was determined using the 2^−ΔΔCq^ method ([@b7-ol-0-0-6688]). All examinations were repeated three times.

### Statistical analysis

All statistical analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Data are presented as the mean ± standard deviation. A Student\'s t test was employed to identify the significance of the difference between groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Treatment with CBC-containing serum reduces the relative viability of human leukemia cells

As demonstrated in [Fig. 1](#f1-ol-0-0-6688){ref-type="fig"}, the relative viability of human leukemia K562 (P=0.00198; [Fig. 1A](#f1-ol-0-0-6688){ref-type="fig"}) and HL60 (P=0.00266; [Fig. 1B](#f1-ol-0-0-6688){ref-type="fig"}) cells at 72 h were significantly reduced by treatment with CBC-containing serum compared with treatment with control serum. The relative viability rates of K562 and HL60 cells treated with CBC-containing serum at 72 h were 80.35±2.64 and 76.43±2.31%, respectively.

### Treatment with CBC-containing serum increases the rate of apoptosis in human leukemia cells

Subsequent to incubating with CBC-containing or control serum for 72 h, the rate of apoptosis in HL60 and K562 cells was analyzed using flow cytometry ([Fig. 2](#f2-ol-0-0-6688){ref-type="fig"}). In HL60 cells, the apoptosis rate was 9.10±2.01% for FBS-treated cells ([Fig. 2A](#f2-ol-0-0-6688){ref-type="fig"}), 18.33±3.13% for the control serum-treated cells ([Fig. 2B](#f2-ol-0-0-6688){ref-type="fig"}) and 28.99±1.33% for the CBC-containing serum-treated cells ([Fig. 2C](#f2-ol-0-0-6688){ref-type="fig"}). In K562 cells, a similar trend to that observed in HL60 cells was identified; the rate was 6.88±1.12% for FBS treated cells ([Fig. 2D](#f2-ol-0-0-6688){ref-type="fig"}), 10.25±3.22% for control serum-treated cells ([Fig. 2E](#f2-ol-0-0-6688){ref-type="fig"}) and 31.38±4.45% for the CBC-containing serum-treated cells ([Fig. 2F](#f2-ol-0-0-6688){ref-type="fig"}).

### Treatment with CBC-containing serum alters the cell cycle distribution of human leukemia cells

Subsequent to incubation with CBC-containing serum, a cell cycle arrest was observed in HL60 and K562 cells at 48--72 h ([Fig. 3](#f3-ol-0-0-6688){ref-type="fig"}). For HL60 cells, the proportion of S phase cells was 19.22% in CBC-containing serum-treated group and 22.33% in the control serum group ([Fig. 3C](#f3-ol-0-0-6688){ref-type="fig"}). In K562 cells, the ratio of S phase cells was 15.42% in CBC-containing serum-treated group and 27.79% in the control serum group ([Fig. 3F](#f3-ol-0-0-6688){ref-type="fig"}).

### Treatment with CBC-containing serum decreases the mRNA expression of VEGF-A in human leukemia cells

As VEGF-A is an important protein in the promotion of angiogenesis, its mRNA expression level was assessed using RT-qPCR. As demonstrated in [Fig. 4](#f4-ol-0-0-6688){ref-type="fig"}, decreased gene expression of VEGF-A mRNA was observed in HL60 and K562 cells treated by CBC-containing serum; the fold changes were 5.67 for K562 cells ([Fig. 4A](#f4-ol-0-0-6688){ref-type="fig"}) and 2.7 for HL60 cells ([Fig. 4B](#f4-ol-0-0-6688){ref-type="fig"}).

### Effect of CBC-containing serum on the mRNA expression of chemotactic and inflammatory genes in human leukemia cells

The mRNA expression of chemotactic and inflammatory genes, including C-C motif chemokine receptor (CCR)2, C-C motif chemokine ligand (CCL)5, CCR4, Dickkopf 3 (DDK3), high mobility group box (HMGB)2, CCR1, CCR5, C-X-C motif chemokine ligand (CXCL)1, DEAD-box helicase (DDX)1, cyclin D1 (CCND1) and interleukin (IL)-6, were detected using RT-qPCR. As demonstrated by [Fig. 5](#f5-ol-0-0-6688){ref-type="fig"}, decreased mRNA expression of CCR2, CCR4, DDK3, HMGB2, CCR1, CCR5 and DDX1 and increased expression of CXCL1 were identified in HL60 cells following treatment with CBC-containing serum ([Fig. 5A](#f5-ol-0-0-6688){ref-type="fig"}). Decreased mRNA expression of CCR2, CCL5, CCR4, DDK3, CCR5, DDX1, CCND1 and IL-6 was identified in K562 cells treated with CBC-containing serum ([Fig. 5B](#f5-ol-0-0-6688){ref-type="fig"}).

Discussion
==========

Seropharmacology is a novel method for the pharmacological study of Chinese *materia medica* ([@b8-ol-0-0-6688]). It has the advantages of *in vitro* experiment, including convenient control of the experimental conditions and the exclusion of interference of internal factors, which facilitate the in-depth study of the mechanism of action for a drug. Seropharmacology reflects the drug metabolism process (including absorption, distribution, metabolism and excretion) of the body, and the drug in the animal serum is in the form of bioactive metabolites with the real pharmacological functions of interest. A number of substances (including secreted cell factor, hormones, antibodies and complement) induced by drug in the body are then retained in the animal serum and can be applied to an *in vitro* experiment, important for the investigation of indirect effects of a drug. In addition, Chinese herbal preparation is likely to be affected by various factors (including chemicals, ions, pH, purity and osmotic pressure) that could result in changes of the outcome of an *in vitro* experiment. Therefore, seropharmacology is quite suitable for pharmacological study on Chinese herbal preparation ([@b9-ol-0-0-6688],[@b10-ol-0-0-6688]). For this reason, CBC-containing serum was prepared for the present study.

CBC is a traditional Chinese medicinal preparation consisting of 11 TCM drugs. Among these 11 drugs, banmao and radix acanthopanax senticosus have been widely applied in TCM cancer therapy ([@b11-ol-0-0-6688]). Banmao is the dried body of the Chinese blister beetle, which has been used from antiquity to the present day in folk medicine ([@b12-ol-0-0-6688],[@b13-ol-0-0-6688]). Banmao can directly inhibit the proliferation of tumor cells. The active constituent of Banmao is cantharidin, which occurs in the dried body at a concentration of 0.6--1.9%. A previous study demonstrated that cantharidin is a strong protein phosphatase and phosphatase 2A inhibitor, and can be used to inhibit cAMP phosphodiesterase activity in hepatoma cells ([@b14-ol-0-0-6688]). Cantharidin has been used to treat various types of tumor, including bowel ([@b15-ol-0-0-6688]), mammary ([@b16-ol-0-0-6688]) and gallbladder ([@b17-ol-0-0-6688]) cancer and leukemia, through inhibiting cellular proliferation and angiogenesis, and inducing cell cycle arrest and apoptosis. In primary hepatic carcinoma cells, cantharidin has been demonstrated to exhibit greater cytotoxic effects against tumor cells compared with those observed in normal cells, and may induce a G2/M cell cycle arrest in carcinoma cells ([@b18-ol-0-0-6688]). Dorn *et al* ([@b19-ol-0-0-6688]) reported that cantharidin induced apoptosis, inhibited proliferation and caused cell cycle arrest in Jurkat cells. Cantharidin has also been reported to exhibit an antitumor effect on acute and chronic myeloid leukemia cells through the induction of apoptosis and the inhibition of proliferation ([@b20-ol-0-0-6688]).

Distinct from the anticancer mechanism of Banmao, stimulation ([@b21-ol-0-0-6688],[@b22-ol-0-0-6688]) and suppression ([@b23-ol-0-0-6688],[@b24-ol-0-0-6688]) of the immune response have been proposed as mechanisms for the antitumor effect of radix acanthopanax senticosus, a plant stem extract, the main anticancer constituents of which are glucosides and polysaccharides. Yoon *et al* ([@b25-ol-0-0-6688]) investigated the antitumor activity of an aqueous acanthopanax senticosus solution; its anti-tumor effect was reported to be associated with the activation of macrophages and natural killer cells ([@b25-ol-0-0-6688]). In TCM clinical treatment, banmao is used to cure patients of their cancer, whereas acanthopanax senticosus is used for cancer prevention ([@b26-ol-0-0-6688]). In the present study, a significant reduction in relative cell viability, an increase in the rate of apoptosis, and a G~0~/G~1~ cell cycle arrest were identified. Therefore, in addition to previous reports that CBC-containing serum can exert an antitumor effect on liver carcinoma cells ([@b27-ol-0-0-6688],[@b28-ol-0-0-6688]), its efficacy on leukemia cells has now been demonstrated.

In the present study, a decreasing level of VEGF-A, the main subtype of VEGF, was identified in HL60 and K562 cells subsequent to treatment with CBC-containing serum. According to previous reports, VEGF-associated angiogenesis performs a critical role in the pathogenesis of hematopoietic malignancies ([@b29-ol-0-0-6688],[@b30-ol-0-0-6688]). VEGF expression may mediate apoptosis resistance and thus, radiotherapy resistance ([@b28-ol-0-0-6688]). Therefore, an effect against VEGF could be an important mechanism for the treatment of leukemia. Our previous study demonstrated that angiogenesis performed a critical role in the pathological process of acute leukemia, and that the expression level of VEGF was closely associated with the degree of angiogenesis and the disease progression in patients with leukemia ([@b31-ol-0-0-6688]). At present, a number of drugs targeting angiogenesis have been successful in the treatment of acute and chronic myeloid leukemia ([@b32-ol-0-0-6688]).

A number of studies ([@b33-ol-0-0-6688]--[@b35-ol-0-0-6688]) have demonstrated that inflammatory and chemotactic genes are closely associated with hematopoietic malignancies, which is why it was considered necessary to assess the status of inflammatory and chemotactic genes in the present study. Downregulation of chemokine gene mRNA expression was identified in HL60 and K562 cells treated with CBC-containing serum; however, differential expression of IL6 was identified between HL60 and K562 cells. This may be due to the different types of leukemia represented by HL60 and K562, as HL60 was established from acute myeloid leukemia and K562 from chronic myeloid leukemia.

In conclusion, a seropharmacological method was used to prepare CBC-containing rat serum to evaluate its effect on human leukemia HL60 and K562 cells. A reduction in cell viability, increased apoptosis and cell cycle arrest were all observed following treatment with CBC-containing serum. Furthermore, the mRNA expression of VEGF-A and chemotactic and inflammatory genes was attenuated following treatment with CBC-containing serum. Additional studies are required to investigate the efficacy of the combination of CBC with other anticancer drugs in the clinical practice.

The present study was supported by Chinese Medicine Scientific Research Foundation of Zhejiang Province (grant no. 2010B501720), Zhejiang Provincial Department of Education (grant no. Y201120523) and Zhejiang Provincial Administration of Traditional Chinese Medicine (grant no. Y201120523).

![Effects of CBC-containing rat serum on the viability of human leukemia cell lines (A) K562 and (B) HL60. \*\*\*P\<0.01 vs. control serum-treated cells. CBC, compound banmao capsule. Error bars represent the standard error of absorbance values of 6 wells.](ol-14-04-4092-g00){#f1-ol-0-0-6688}

![Effects of CBC-containing rat serum on the apoptosis of human leukemia cell lines HL60 and K562. HL60 cells treated with (A) FBS (no treatment), (B) control rat serum or (C) CBC-containing rat serum; K562 cells treated with (D) FBS, (E) control rat serum or (F) CBC-containing rat serum. CBC, compound banmao capsule; FBS, fetal calf serum; PI, propidium iodide; FITC, fluorescein isothiocyanate.](ol-14-04-4092-g01){#f2-ol-0-0-6688}

![Effects of CBC-containing rat serum on the cell cycle of human leukemia cell lines HL60 and K562. Subsequent to treatment with CBC-containing or vehicle control rat serum, the cells were processed with cell cycle analysis by flow cytometry. K562 cells treated with (A) control rat serum or (B) CBC-containing rat serum; (C) histogram of the differences in cell cycle distribution between (A) and (B). HL60 cells treated with (D) control rat serum or (E) CBC-containing rat serum; (F) histogram of the differences in cell cycle distribution between (D) and (E). CBC, compound banmao capsule; ctrl, control.](ol-14-04-4092-g02){#f3-ol-0-0-6688}

![Effects of CBC-containing rat serum on the mRNA expression of VEGF-A in human leukemia cell lines. The differences in VEGF-A mRNA expression between cells treated with control rat serum or CBC-containing rat serum were assessed in (A) K562 cells and (B) HL60 cells. \*\*\*P\<0.01 compared with the control. Error bars represent the standard error of triplicate wells. CBC, compound banmao capsule; VEGF-A, vascular endothelial growth factor A.](ol-14-04-4092-g03){#f4-ol-0-0-6688}

![Effects of CBC-containing rat serum on the expression of chemotactic and inflammatory genes in human leukemia cell lines. The fold changes of mRNA (CBC serum/control) in (A) HL60 cells and (B) K562 cells subsequent to CBC-containing serum treatment. CBC, compound banmao capsule; CCR, C-C motif chemokine receptor; CCL, C-C motif chemokine ligand; DDK, Dickkopf; HMGB, high mobility group box; CXCL, C-X-C motif chemokine ligand; DDX, DEAD box helicase; CCND, cyclin D1; IL, interleukin.](ol-14-04-4092-g04){#f5-ol-0-0-6688}

###### 

The primers used in the reverse transcription-quantitative polymerase chain reaction for detection of relative expression levels of genes.

  Genes     Primers (5′ to 3′)
  --------- ----------------------------
  VEGF-F    CGCAGCTACTGCCATCCAAT
  VEGF-R    GTGAGGTTTGATCCGCATAATCT
  CCR1-F    TCCTGCTGACGATTGACAGGTA
  CCR1-R    GTGCCCGCAAGGCAAAC
  CCR2-F    GCGTTTAATCACATTCGAGTGTTT
  CCR2-R    CCACTGGCAAATTAGGGAACAA
  CCR4-F    CAATACTGTGGGCTCCTCCAA
  CCR4-R    ATCCATGGTGGACTGCGTGTA
  CCR5-F    GCTGGTCATCCTCATCCTGATAA
  CCR5-R    ATGGCCAGGTTGAGCAGGTA
  CCL5-F    TCCCGAACCCATTTCTTCTCT
  CCL5-R    CCCAGCAGTCGTCTTTGTCA
  CXCL1-F   AGGGAATTCACCCCAAGAAC
  CXCL1-R   ACTATGGGGGATGCAGGATT
  CCND1-F   GGCGGAGGAGAACAAACAGA
  CCND1-R   TGGCACAAGAGGCAACGA
  DDX1-F    AGCCAAGATGCAGGAAAGATG
  DDX1-R    GCTATAAAGGCCATGTGGATATTTTG
  DDK3-F    GAAACTGCTCTGGTCTTCACTAGCT
  DDK3-R    CTCCTCGTCCATCAGGGATCT
  HMGB2-F   CTTGGCACGATATGCAGCAA
  HMGB2-R   CAGCCAAAGATAAACAACCATATGA
  IL6-F     TGCGTCCGTAGTTTCCTTCT
  IL6-R     GCCTCAGACATCTCCAGTCC

F, forward; R, reverse.
